Naviswiss Receives FDA 510k Clearance for Naviplan

Naviswiss, a Swiss-based medical technology company receives clearance from the FDA to market Naviplan in the United States. Naviplan is a digital pre-operative planning application enabling orthopedic surgeons to perform navigated CT-based total hip replacement surgery. This has the potential to improve accuracy, predictability and provide seamless documentation of the outcome.

Naviswiss, the technology leader in miniaturized surgical navigation solutions, supports orthopedic surgeons in accurately positioning hip replacement implants. The Naviplan hip application is CT-based and assists the surgeon in the optimal positioning of the joint implants, automatic 3D segmentation and advanced image processing. Naviplan outputs the pre-operative plan into the Naviswiss navigation platform for accurate surgical execution.

“Naviplan and CT-based Navigation are an important addition to the Naviswiss portfolio and completes our offering for navigated hip replacement,” said Jan Stifter, Naviswiss CEO. “We now have two patient-specific options where the surgeon determines the best application for the procedure. CT-based Navigation may be needed in difficult deformity cases while kinematic registration may be preferred in more traditional surgeries. The surgeon can rely on highly accurate guidance in placing the acetabular components.”

Naviswiss is releasing the CT-based Navigation and Naviplan to orthopedic care centers in the United States over the course of the fourth quarter 2021.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.